Precipio, Inc. (PRPO) Reaches $0.88 1 Year Low; Dynatronics (DYNT) Sentiment Is 2

February 11, 2018 - By Linda Rogers

Dynatronics Corporation designs, manufactures, distributes, and markets physical medicine products in the United States and internationally. The company has market cap of $20.34 million. It makes and sells electrotherapy, therapeutic ultrasound, phototherapy, thermal therapy, iontophoresis devices, and other modalities; traction therapy equipment; medical supplies and soft goods, including hot and cold packs, lumbar rolls, exercise balls, wrist splints, ankle weights, cervical collars and pillows, slings, bolsters, positioning wedges, back cushions, weight racks, rehabilitation products, back and wrist braces. It currently has negative earnings. The firm also sells mat platforms, and other rehabilitation and athletic training room products.

The stock of Precipio, Inc. (NASDAQ:PRPO) hit a new 52-week low and has $0.81 target or 8.00% below today’s $0.88 share price. The 6 months bearish chart indicates high risk for the $8.97 million company. The 1-year low was reported on Feb, 11 by Barchart.com. If the $0.81 price target is reached, the company will be worth $717,200 less. The stock decreased 14.43% or $0.1486 during the last trading session, reaching $0.8814. About 774,448 shares traded or 1093.46% up from the average. Precipio, Inc. (NASDAQ:PRPO) has 0.00% since February 11, 2017 and is . It has underperformed by 16.70% the S&P500.




Precipio, Inc. provides diagnostic information to physicians and their patients worldwide. The company has market cap of $8.97 million. It has collaborations with academic institutions specializing in cancer research, diagnostics, and treatment. It currently has negative earnings.

The stock decreased 0.23% or $0.0059 during the last trading session, reaching $2.5939. About 3,933 shares traded. Dynatronics Corporation (DYNT) has risen 1.94% since February 11, 2017 and is uptrending. It has underperformed by 14.76% the S&P500.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: